Skip to main content

Eli Lilly and Company Oncology revenue

  • LLY · NYSE
  • Pharmaceuticals
  • S&P 500
$1443.50+1.14%Close 13 Nov 2026 · Market value $1.36T

Oncology revenue at Eli Lilly and Company came to $1.5B for the quarter to 30 Sep 2026, up 10.4% from a year earlier.

As Eli Lilly and Company reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 29 Oct 2026.

By quarter

$1.1BDec 2023$998.3MMar 2024$1.3BJun 2024$1.3BSep 2024$1.5BDec 2024$1.0BMar 2025$1.4BJun 2025$1.4BSep 2025$1.5BDec 2025$1.2BMar 2026$1.5BJun 2026$1.5BSep 2026
Eli Lilly and Company Oncology revenue, every reported period
Period endingOncology revenueChange on a yearFiled
30 Sep 2026$1.5Bup 10.4%29 Oct 2026
30 Jun 2026$1.5Bup 3.8%5 Aug 2026
31 Mar 2026$1.2Bup 17.4%30 Apr 2026
31 Dec 2025$1.5Bup 3.0%12 Feb 2026
30 Sep 2025$1.4Bup 6.2%30 Oct 2025
30 Jun 2025$1.4Bup 11.3%7 Aug 2025
31 Mar 2025$1.0Bup 4.8%1 May 2025
31 Dec 2024$1.5Bup 32.6%19 Feb 2025
30 Sep 2024$1.3Bup 29.2%30 Oct 2024
30 Jun 2024$1.3Bup 36.4%8 Aug 2024
31 Mar 2024$998.3Mup 32.5%30 Apr 2024
31 Dec 2023$1.1Bup 25.4%21 Feb 2024
30 Sep 2023$1.0Bup 36.7%2 Nov 2023
30 Jun 2023$935.0Mup 14.2%8 Aug 2023
31 Mar 2023$753.4Mdown 3.9%27 Apr 2023
31 Dec 2022$882.7Mup 6.7%22 Feb 2023
30 Sep 2022$732.7Mup 0.2%1 Nov 2022
30 Jun 2022$819.0Mdown 1.1%4 Aug 2022
31 Mar 2022$783.7Mup 22.0%29 Apr 2022
31 Dec 2021$827.1Mup 7.6%23 Feb 2022
30 Sep 2021$730.9Mup 7.1%27 Oct 2021
30 Jun 2021$828.3Mup 21.3%3 Aug 2021
31 Mar 2021$642.5Mdown 2.3%30 Apr 2021
31 Dec 2020$769.0Mup 12.3%17 Feb 2021
30 Sep 2020$682.5Mup 6.6%28 Oct 2020
30 Jun 2020$682.7Mdown 1.0%31 Jul 2020
31 Mar 2020$657.9Mup 10.8%1 May 2020
31 Dec 2019$684.6Mup 3.4%19 Feb 2020
30 Sep 2019$640.2Mup 3.3%25 Oct 2019
30 Jun 2019$689.8Mup 12.9%2 Aug 2019
31 Mar 2019$593.9Mup 16.4%2 May 2019
31 Dec 2018$662.0M—19 Feb 2019
30 Sep 2018$619.8M—6 Nov 2018
30 Jun 2018$611.1M—25 Jul 2018
31 Mar 2018$510.2M—27 Apr 2018

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Eli Lilly and Company: Cardiometabolic Health revenue · Zepbound revenue · Mounjaro revenue · Verzenio revenue · Immunology revenue · Jardiance revenue · Trulicity revenue · Taltz revenue · Neuroscience revenue · United States revenue · Outside U.S. revenue · Europe revenue · Rest of world revenue · China revenue · Japan revenue · financial statements

Every KPI and segment of LLY, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.